What is the clinical relevance of drug-resistant pneumococcus?

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 3, 2016, Pages 227-234

  Cillóniz, Catia ^a   Ardanuy, Carmen ^a,b   Vila, Jordi ^c,d   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

antimicrobial resistance; pneumococcus; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINCOSAMIDE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; ANTIINFECTIVE AGENT; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BETA LACTAM RESISTANT STREPTOCOCCUS PNEUMONIAE; DRUG MISUSE; EXTENSIVELY RESISTANT STREPTOCOCCUS PNEUMONIAE; HUMAN; MACROLIDE RESISTANT STREPTOCOCCUS PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT STREPTOCOCCUS PNEUMONIAE; NONHUMAN; PENICILLIN RESISTANCE; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PNEUMOCOCCAL INFECTION; REVIEW; RISK FACTOR; SEROTYPE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; IMMUNOLOGY; PNEUMOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 84959162703     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000262     Document Type: Review

References (52)

1. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-1746.
2. Jansen AG, Rodenburg GD, van der EA, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 2009; 49:e23-e29.
3. Varon E, Mainardi JL, Gutmann L. Streptococcus pneumoniae: still a major pathogen. Clin Microbiol Infect 2010; 16:401.
4. World Health Organization (WHO). Progress in introduction of pneumococcal conjugate vaccine worldwide, 2000-2012. 88(17), p. 173-180; 2013.
5. Burgos J, Falco V, Borrego A, et al. Impact of the emergence of nonvaccine pneumococcal serotypes on the clinical presentation and outcome of adults with invasive pneumococcal pneumonia. Clin Microbiol Infect 2013; 19:385-391.
6. Rock C, Sadlier C, Fitzgerald J, et al. Epidemiology of invasive pneumococcal disease and vaccine provision in a tertiary referral center. Eur J Clin Microbiol Infect Dis 2013; 32:1135-1141.
7. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol 2006; 4:36-45.
8. Lynch JP III, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009; 30:210-238.
9. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009; 47:1012-1020.
10. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 2008; 8:785-795.
11. Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 2008; 9:229-241.
12. Goossens H, Ferech M, Vander SR, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365:579-587.
13. Kuster SP, Rudnick W, Shigayeva A, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis 2014; 59:944-952.
14. Navarro TA, Dias JG, Quinten C, et al. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the postheptavalent conjugate vaccine era. Vaccine 2014; 32:3644-3650.
15. Tomic V, Dowzicky MJ. Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008). Ann Clin Microbiol Antimicrob 2014; 13:52.
16. Japan Nosocomial Infections Surveillance (JANIS); Clinical Laboratory Division. Annual Open Report 2013. http://www.nih-janis.jp/english/report/open-report/2013/3/1/ken-Open-Report-Eng-201300.pdf. [Accessed 28 November 2015].
17. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics. J Antimicrob Chemother 1992; 30:279-288.
18. Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013; 75:107-109.
19. Cilló niz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 2015; 191:1265-1272.
20. Calatayud L, Ardanuy C, Tubau F, et al. Serotype and genotype replacement among macrolide-resistant invasive pneumococci in adults: mechanisms of resistance and association with different transposons. J Clin Microbiol 2010; 48:1310-1316.
21. Domenech A, Tirado-Velez JM, Fenoll A, et al. Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006. Antimicrob Agents Chemother 2014; 58:2393-2399.
22. Kang CI, Song JH, Kim SH, et al. Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study. Eur J Clin Microbiol Infect Dis 2014; 33:55-59.
23. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288-1297.
24. European Centre for Disease Prevention and Control (ECDC). Antimicrobial resistance surveillance in Europe; 2012. http://ecdc.europa.eu/en/publica-tions/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf. [Accessed 8 December 2015].
25. Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (AN-SORP) study. Antimicrob Agents Chemother 2012; 56:1418-1426.
26. Rodriguez-Avial I, Ramos B, Rios E, et al. Clonal spread of levofloxacin-resistant Streptococcus pneumoniae invasive isolates in Madrid, Spain, 2007 to 2009. Antimicrob Agents Chemother 2011; 55:2469-2471.
27. Sanz JC, Cercenado E, Marin M, et al. Multidrug-resistant pneumococci (serotype 8) causing invasive disease in HIV+ patients. Clin Microbiol Infect 2011; 17:1094-1098.
28. Golden AR, Rosenthal M, Fultz B, et al. Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13. J Antimicrob Chemother 2015; 70:2199-2202.
29. Adrian PV, Klugman KP. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41:2406-2413.
30. Gillis LM, White HD, Whitehurst A, Sullivan DC. Vancomycin-tolerance among clinical isolates of Streptococcus pneumoniae in Mississippi during 1999-2001. Am J Med Sci 2005; 330:65-68.
31. Moscoso M, Domenech M, Garcia E. Vancomycin tolerance in Gram-positive cocci. Environ Microbiol Rep 2011; 3:640-650.
32. Mera RM, Miller LA, Daniels JJ, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 2005; 51:195-200.
33. Thornsberry C, Brown NP, Draghi DC, et al. Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. Postgrad Med 2008; 120:32-38.
34. Lee S, Lee K, Kang Y, Bae S. Prevalenceof serotype and multidrug-resistance of Streptococcus pneumoniae respiratory tract isolates in 265 adults and 36 children in Korea, 2002-2005. Microb Drug Resist 2010; 16:135-142.
35. Gherardi G, Fallico L, Del GM, et al. Antibiotic-resistant invasive pneumo-coccal clones in Italy. J Clin Microbiol 2007; 45:306-312.
36. van der LM, Perniciaro S, Imohl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis 2015; 15:207.
37. Cho SY, Baek JY, Kang CI, et al. Extensively drug-resistant Streptococcus pneumoniae, South Korea, 2011-2012. Emerg Infect Dis 2014; 20:869-871.
38. Torres A, Cillóniz C, Ferrer M, et al. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J 2015; 45:1353-1363.
39. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother 2015; 16:159-177.
40. Tin Tin HM, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis 2015; 15:419.
41. Fenoll A, Granizo JJ, Gimenez MJ, et al. Secular trends (1990-2013) in serotypes and associated nonsusceptibility of S. pneumoniae isolates causing invasive disease in the pre/postera of pneumococcal conjugate vaccines in Spanish regions without universal paediatric pneumococcal vaccination. Vaccine 2015; 33:5691-5699.
42. Pallares R, Fenoll A, Linares J. The epidemiology of antibiotic resistance in Streptococcus pneumoniae and the clinical relevance of resistance to ce-phalosporins, macrolides and quinolones. Int J Antimicrob Agents 2003; 22 (Suppl 1):S15-S24.
43. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230-237.
44. Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42:788-797.
45. Falagas ME, Siempos II, Bliziotis IA, Panos GZ. Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review. Mayo Clin Proc 2006; 81:1567-1574.
46. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalos-porin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474-480.
47. Zhanel GG, Wolter KD, Calciu C, et al. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneu-moniae: analysis of Phase 3 clinical trial data. J Antimicrob Chemother 2014; 69:2835-2840.
48. Daneman N, McGeer A, Green K, Low DE. Macrolide resistance in bactere-mic pneumococcal disease: implications for patient management. Clin Infect Dis 2006; 43:432-438.
49. Patel SN, McGeer A, Melano R, et al. Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Antimicrob Agents Chemother 2011; 55:3703-3708.
50. Ip M, Chau SS, Chi F, et al. Longitudinally tracking fluoroquinolone resistance and its determinants in penicillin-susceptible and-nonsusceptible Streptococcus pneumoniae isolates in Hong Kong, 2000 to 2005. Antimicrob Agents Chemother 2007; 51:2192-2194.
51. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005; 41:118-121.
52. de la Campa AG, Ardanuy C, Balsalobre L, et al. Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis 2009; 15:905-911.